Ads
related to: biotech- Molecular Biology Suite
Build, share, and record DNA, RNA &
amino acid sequences in the cloud
- Workflows LIMS
Organize, optimize and measure your
processes in our Biotech R&D Cloud
- Pricing
Affordable & flexible pricing for
every R&D organization and industry
- Customer Stories
Discover how 200k+ scientists
unlock discovery & innovation
- Molecular Biology Suite
cdwg.com has been visited by 100K+ users in the past month
Search results
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Zacks via Yahoo Finance· 4 hours agoVir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and...
CollPlant Biotechnologies First Quarter 2024 Earnings: Misses Expectations
Simply Wall St. via Yahoo Finance· 1 day agoCollPlant Biotechnologies (NASDAQ:CLGN) First Quarter 2024 Results Key Financial Results Revenue:...
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Zacks via Yahoo Finance· 1 day agoThe iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded...
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
Benzinga via Yahoo Finance· 1 day agoOn Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2...
Biotech Venture Financing Hasn’t Loosened Up Yet
The Wall Street Journal· 11 hours agoBiotechnology entrepreneurs early this year hoped for venture investment in their industry to recover. They’re still waiting.
National Security Commission on Emerging Biotechnology Announces Introduction of Agricultural Bills...
JD Supra· 14 hours agoSenators Alex Padilla (D-CA) and Todd Young (R-IN) and Representatives Stephanie Bice (R-OK) and Ro Khanna (D-CA) — for introducing the legislative recommendations from its first report. The ...
NIAID funds second year of Pluri's radiation therapy studies By Investing.com
Investing.com· 2 hours agoPluri Inc. (NASDAQ:PLUR) (TASE:PLUR), a biotechnology firm, has received continued funding from the...
Vir stock gains on hepatitis drug data (NASDAQ:VIR)
Seeking Alpha· 1 day agoVir Biotechnology (VIR) stock gains as its hepatitis therapy tobevibart developed with Xencor shows early signs of efficacy in a Phase 2 trial. Read more...
Why biotech's big convention isn't returning to San Francisco. (Hint: It has nothing to do with a...
The Business Journals· 8 hours agoInstead, said BIO CEO John Crowley, BIO has contracts in San Diego, where 19,000 attendees this week...
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Zacks via Yahoo Finance· 2 days agoThe First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a passively...
